Paradigm Capital Management Inc. NY purchased a new stake in shares of Accendra Health, Inc. (NYSE:ACH - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,536,699 shares of the company's stock, valued at approximately $8,676,000. Paradigm Capital Management Inc. NY owned about 3.30% of Accendra Health at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in ACH. Walleye Capital LLC bought a new stake in Accendra Health in the 1st quarter worth approximately $27,000. Hsbc Holdings PLC bought a new position in shares of Accendra Health during the 1st quarter valued at approximately $34,000. Abel Hall LLC purchased a new position in shares of Accendra Health in the first quarter valued at $44,000. Keybank National Association OH purchased a new position in shares of Accendra Health in the first quarter valued at $46,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Accendra Health in the first quarter worth $50,000.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on ACH shares. Citigroup downgraded shares of Accendra Health from a "buy" rating to a "neutral" rating and decreased their price target for the company from $4.50 to $1.50 in a research note on Monday, August 10th. Robert W. Baird set a $1.50 target price on shares of Accendra Health and gave the stock a "neutral" rating in a report on Tuesday, August 11th. Weiss Ratings cut shares of Accendra Health from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, August 6th. Finally, UBS Group decreased their target price on shares of Accendra Health from $4.50 to $1.50 and set a "neutral" rating on the stock in a research report on Thursday, August 13th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus price target of $1.50.
Check Out Our Latest Report on ACH
Accendra Health Trading Down 5.4%
Shares of Accendra Health stock opened at $1.14 on Tuesday. The stock has a market cap of $87.28 million, a PE ratio of -0.29 and a beta of 1.58. The business has a 50 day moving average of $2.83. Accendra Health, Inc. has a one year low of $0.93 and a one year high of $5.69.
Accendra Health (NYSE:ACH - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The company had revenue of $613.23 million for the quarter. Accendra Health had a negative net margin of 11.41% and a negative return on equity of 4.02%. Equities analysts expect that Accendra Health, Inc. will post -0.03 EPS for the current year.
Accendra Health Company Profile
(
Free Report)
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Accendra Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accendra Health wasn't on the list.
While Accendra Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
